7 stories mentioning HKG:6938Updated 11d ago
Every FINWIRES story that references HKG:6938, newest first.
Suzhou Ribo Life Science (HKG:6938) said the European Medicines Agency has approved a Phase 2b clinical trial of its core product, vortosiran, for stroke prevention in patients with atrial fibrillation, according to a Tuesday Hong Kong bourse filing.The approval allows the company to begin the global multi-regional ORBIT-XI-AF study, advancing vortosiran into the next stage of clinical development.
Suzhou Ribo Life Science (HKG:6938) reported positive Phase 2a results for its investigational therapy vortosiran (RBD4059) in patients with chronic coronary artery disease.The study showed the small interfering RNA therapy was generally well tolerated and achieved dose-dependent, long-lasting suppression of coagulation factor XI activity in patients receiving aspirin therapy, with no treatment-related serious adverse events or major bleeding reported, according to a Hong Kong bourse filing on Wednesday.
Suzhou Ribo Life Science (HKG:6938) achieved the first candidate drug nomination milestone under a licensing agreement with Madrigal Pharmaceuticals, according to a Thursday filing.The milestone is to advance cutting-edge RNA therapeutics for liver diseases, with a focus on metabolic dysfunction-associated steatohepatitis.The parties will immediately initiate IND-enabling studies to support planned clinical studies.
Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.
Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.
Suzhou Ribo Life Science (HKG:6938) achieved another milestone under a research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, according to a Hong Kong bourse filing Wednesday.The companies are researching therapies for metabolic dysfunction-associated steatohepatitis, or MASH, a serious and progressive form of fatty liver disease.The milestone underscores the commercial potential of Ribo Life Science's siRNA platform, the firm said.
Suzhou Ribo Life Science (HKG:6938) said it submitted a phase 2b clinical trial application to the European Medicines Agency for its core product Vortosiran for stroke prevention in atrial fibrillation, according to a Tuesday Hong Kong bourse filing.Vortosiran targets factor XI to reduce clotting activity and may offer thromboembolic protection with lower bleeding risk, the filing said.
